Hubbry Logo
AlbuminAlbuminMain
Open search
Albumin
Community hub
Albumin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Albumin
Albumin
Albumin
View on Wikipedia
from Wikipedia

Serum albumin family
Structure of serum albumin.[1][2]
Identifiers
SymbolSerum_albumin
PfamPF00273
Pfam clanCL0282
InterProIPR014760
SMARTSM00103
PROSITEPS51438
SCOP21ao6 / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
PDB1ao6​, 1bj5​, 1bke​, 1bm0​, 1e78​, 1e7a​, 1e7b​, 1e7c​, 1e7e​, 1e7f​, 1e7g​, 1e7h​, 1e7i​, 1gni​, 1gnj​, 1h9z​, 1ha2​, 1hk1​, 1hk2​, 1hk3​, 1hk4​, 1hk5​, 1j78​, 1j7e​, 1kw2​, 1kxp​, 1lot​, 1ma9​, 1n5u​, 1o9x​, 1tf0​, 1uor​, 1ysx​, 2bx8​, 2bxa​, 2bxb​, 2bxc​, 2bxd​, 2bxe​, 2bxf​, 2bxg​, 2bxh​, 2bxi​, 2bxk​, 2bxl​, 2bxm​, 2bxn​, 2bxo​, 2bxp​, 2bxq​, 2i2z​, 2i30​, 2vdb​, 2vue​, 2vuf​, 3b9l​, 3b9m​

Albumin is a family of globular proteins, the most common of which are the serum albumins. All of the proteins of the albumin family are water-soluble, moderately soluble in concentrated salt solutions, and experience heat denaturation. Albumins are commonly found in blood plasma and differ from other blood proteins in that they are not glycosylated. Substances containing albumins are called albuminoids.

A number of blood transport proteins are evolutionarily related in the albumin family, including serum albumin, alpha-fetoprotein, vitamin D-binding protein and afamin.[3][4][5] This family is only found in vertebrates.[6]

Albumins in a less strict sense can mean other proteins that coagulate under certain conditions. See § Other albumin types for lactalbumin, ovalbumin and plant "2S albumin".

Function

[edit]

Albumins in general are transport proteins that bind to various ligands and carry them around.[6] Human types include:

The four canonical human albumins are arranged on chromosome 4 region 4q13.3 in a tandem manner.[10]

Classification

[edit]

Albumins found in animals can be divided into six subfamilies by phylogeny. The Vitamin-D binding proteins occupy families 1–3. The other albumins are mixed among each other in families 4–6. ECM1 is in family 6.[6]

In addition to their medical use, serum albumins are valued in biotechnology. Bovine serum albumin is usually used, although versions from humans and genetically modified rice are also used to reduce animal cruelty.

Other albumin types

[edit]

A few other proteins are also sometimes called albumins. They are not in the same family as vertebrate albumins:

Structure

[edit]

The 3D structure of human serum albumin has been determined by X-ray crystallography to a resolution of 2.5 ångströms (250 pm).[1] Albumin is a 65–70 kDa protein.

Albumin comprises three homologous domains that assemble to form a heart-shaped protein.[2] Each domain is a product of two subdomains that possess common structural motifs.[2] The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chemistry. Structurally, the serum albumins are similar, each domain containing five or six internal disulfide bonds.

Forensic detection

[edit]

Worldwide, certain traditional Chinese medicines contain wild bear bile, banned under CITES legislation. Dip sticks, similar to common pregnancy tests, have been developed to detect the presence of bear albumin in traditional medicine products, indicating that bear bile had been used in their creation.[12]

Etymology

[edit]

Albumin is pronounced /ˈælbjʊmɪn/; formed from Latin: albumen[13] "egg white", itself derived from the latin albus: white.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Albumin

View on Grokipedia
from Grokipedia
Albumin denotes a family of water-soluble globular proteins, with serum albumins representing the predominant members in vertebrate blood plasma, characterized by their monomeric structure, acidic amino acid content, and ability to crystallize readily. Human serum albumin (HSA), the most abundant circulating protein at concentrations of 35-50 g/L, is a 585-amino-acid polypeptide synthesized exclusively by hepatocytes in the liver, featuring a molecular mass of 66.5 kDa and a three-domain architecture comprising six α-helical subdomains that confer ligand-binding pockets for diverse molecules. As the principal contributor to plasma oncotic pressure, HSA sustains vascular volume by counteracting hydrostatic forces and averting edema, while also facilitating the transport of unesterified fatty acids, bilirubin, metal ions, and pharmaceuticals through specific reversible binding sites. Its multifaceted functionality extends to non-enzymatic antioxidant defense via free radical scavenging, esterase-like hydrolysis of esters and amides, and modulation of endothelial glycocalyx integrity, highlighting its indispensable role in systemic homeostasis and therapeutic applications such as volume expansion in hypovolemia.

Molecular Structure and Properties

Primary Sequence and Domains

(HSA) is a single polypeptide chain comprising 585 in its mature form, derived from a precursor with a 24-residue . The primary sequence encodes a protein that folds into a predominantly α-helical structure, with approximately 67% of residues in helices, lacking N-linked sites typical of many plasma proteins, which distinguishes it from glycoproteins such as immunoglobulins. The tertiary structure of HSA, determined by at 2.5 resolution, reveals three homologous domains (I, II, and III), each divided into s A and B connected by flexible loops. These domains form a heart-shaped with dimensions of approximately 80 × 80 × 30 , stabilized by 17 intrachain bonds (16 intra-domain and 1 inter-domain between domains I and III) involving 34 of the 35 residues. The sole free at position 34 (Cys34) is located in subdomain IB and remains reactive, while the is acetylated, contributing to its stability and specific biochemical properties. Orthologous serum albumins, such as (BSA), exhibit high sequence conservation, with HSA and BSA sharing about 76% identity, reflecting evolutionary preservation of the domain architecture despite species-specific variations. This homology underscores the structural , where each domain consists of a series of nine helices forming double loops bridged by disulfides, as confirmed in crystallographic studies.

Physicochemical Characteristics

Human serum albumin (HSA) is a monomeric with a molecular weight of approximately 66.5 kDa, consisting of 585 residues. Its (pI) is around 4.7, reflecting a net negative charge at physiological due to 98 and residues compared to 83 positively charged and residues. HSA exhibits high in water, exceeding 40 g/L at neutral , which is attributed to its acidic content and globular structure. At physiological , HSA carries a high negative charge, facilitating electrostatic interactions in solution. Conformational changes occur under low or elevated temperatures, leading to expansion and uncoiling of the , which is reversible below denaturation thresholds as observed in and spectroscopic studies. Thermal denaturation profiles show pH-dependent stability, with maximum stability temperatures varying continuously and often below 0°C across pH ranges, while binding enhances thermal stability but introduces complexity in unfolding pathways. modulates these transitions by influencing electrostatic repulsion among charged residues. Ligand-binding sites, notably Sudlow sites I and II, have been characterized through of HSA complexes, revealing specific pockets in subdomains IIA and IIIA for drug and interactions. Sudlow site I, the primary high-affinity site, features positively charged residues like Lys-195 and Arg-218 at its entrance, enabling binding of diverse ligands via hydrophobic and electrostatic forces. These sites underscore HSA's versatility in solution, independent of contexts.

Physiological Functions

Maintenance of Oncotic Pressure

Albumin constitutes the predominant contributor to plasma colloid osmotic pressure (COP), providing approximately 75-80% of the total, with normal plasma COP ranging from 25 to 30 mmHg in humans. This oncotic force arises from the osmotic effect of albumin's relatively low molecular weight (approximately 66.5 kDa) and high concentration (35-50 g/L), which draws water into the vascular compartment to counterbalance capillary hydrostatic pressure (typically 10-40 mmHg arteriolar to venular). The resulting equilibrium prevents excessive transudation of fluid into interstitial spaces, maintaining vascular volume through principles of osmotic mechanics where solute-impermeant colloids like albumin generate a pressure gradient across semipermeable endothelial barriers. Starling's equation formalizes this dynamic, quantifying net transcapillary fluid flow as Jv=Kf[(Pc−Pi)−σ(πc−πi)]J_v = K_f [(P_c - P_i) - \sigma (\pi_c - \pi_i)], where πc\pi_c (plasma oncotic pressure) is dominated by albumin, σ\sigma is the (near 1 for albumin due to endothelial selectivity), and subscripts denote (c) and (i) compartments. Empirical measurements confirm that albumin's contribution ensures πc\pi_c opposes hydrostatic gradients, with direct osmometry showing COP reductions proportional to albumin dilution, thereby linking molecular concentration causally to fluid retention. Albumin's net negative charge (pI ≈ 4.7) further amplifies effective COP via the Gibbs-Donnan effect, where charged protein repels co-ions (anions like ) across membranes while attracting counter-ions (cations like sodium), asymmetrically elevating osmotic activity beyond neutral solute expectations. This electrochemical asymmetry enhances intravascular retention, as verified by ion distribution studies showing Donnan potentials that increase measured COP by 10-20% in protein solutions. In scenarios of capillary leak, where albumin extravasates, empirical observations link the resultant COP deficit to net fluid shifts and tissue swelling, underscoring the protein's mechanistic primacy. The primacy of albumin in oncotic regulation is evolutionarily conserved across vertebrates, with and functional homology preserved from to mammals, reflecting adaptive selection for efficient vascular over less osmotically potent . Comparative analyses reveal albumin's domain structure and ligand-binding properties enabling sustained COP generation, independent of species-specific globulin variations, as evidenced by phylogenetic distributions where albumin orthologs uniformly dominate plasma oncotics.

Molecular Transport and Binding

Human serum albumin (HSA) functions as a versatile carrier protein, binding a diverse array of hydrophobic s through reversible non-covalent interactions at multiple specific sites, as elucidated by techniques such as equilibrium dialysis, , and . It accommodates up to seven long-chain molecules across distinct binding pockets, primarily in subdomains IB, IIA, and IIIA, with primary high-affinity sites (FA1–FA7) exhibiting association constants ranging from 10^5 to 10^7 M^{-1} depending on fatty acid structure. binds with high affinity (Kd ≈ 10^{-7} to 10^{-8} M) mainly at the FA1 site in subdomain IB, while occupies the FA1 site with a Kd of approximately 10^{-8} M, facilitating its transport and preventing oxidative damage. Hormones such as thyroxine (T4) interact with HSA at low-affinity sites in subdomain IIIA, characterized by a dissociation constant (Kd) of about 2 × 10^{-6} M, serving as a secondary reservoir after primary binding to . Exogenous compounds, including drugs like (binding to Sudlow site I in subdomain IIA with Kd ≈ 10^{-6} M) and (Sudlow site II in subdomain IIIA with Kd ≈ 10^{-5} M), occupy these orthosteric sites, with binding affinities quantified via spectroscopic methods. Allosteric modulation arises from interdomain communication, where occupancy of sites alters the conformation and affinity at drug-binding pockets, as demonstrated by microcalorimetric studies showing competitive and cooperative effects. Ligand delivery to tissues is enabled by HSA's conformational dynamics, including pH-dependent transitions from the neutral (N) form at physiological to the fast-migrating (F) form in acidic environments (pH < 4.3), which reduces binding affinity and promotes ligand release. This isomerization, coupled with localized pH gradients in capillaries and endosomes, facilitates empirical calculations of free ligand fractions critical for pharmacokinetics, where unbound concentrations drive diffusion and receptor interactions. Binding affinities for certain anionic , such as long-chain fatty acids, increase at mildly acidic (e.g., 6.0–7.0) due to enhanced electrostatic interactions with protonated residues.

Antioxidant and Protective Roles

Human serum albumin (HSA) functions as a primary circulating antioxidant through its free thiol group at cysteine residue 34 (Cys34), which acts as a sacrificial reductant to scavenge reactive oxygen species (ROS) and reactive nitrogen species (RNS), including hypochlorous acid (HOCl) and peroxynitrite (ONOO⁻). This residue, comprising approximately 80% of plasma free thiols, undergoes oxidation to sulfenic acid intermediates, enabling it to trap multiple equivalents of oxidants per molecule and contributing over 40% of HSA's total in vivo antioxidant effect. Electron paramagnetic resonance (EPR) spectroscopy has confirmed Cys34's role in forming protein radicals upon exposure to ROS, with scavenging efficiency modulated by physiological antioxidants like glutathione. HSA accounts for more than 70% of serum's free radical-trapping capacity, as quantified by oxygen radical absorbance capacity (ORAC) assays measuring peroxyl radical scavenging in plasma. In plasma, HSA preferentially consumes the majority of chlorinated oxidants like HOCl, protecting other biomolecules from oxidative damage through nucleophilic attack at Cys34 and other residues. Additionally, HSA binds transition metals such as copper and zinc, sequestering them to inhibit Fenton-like reactions that generate highly reactive hydroxyl radicals from hydrogen peroxide. Glycation of HSA at lysine residues forms advanced glycation end products (AGEs), which reduce its redox potential and impair Cys34-mediated scavenging, thereby diminishing baseline free radical quenching that supports endothelial integrity. Despite this vulnerability, unmodified HSA maintains plasma redox homeostasis by quenching ROS before they propagate to vascular endothelium, as evidenced by in vitro assays showing preserved antioxidant activity against H₂O₂ and ONOO⁻.

Classification and Variants

Serum Albumins Across Species

Serum albumins are phylogenetically conserved across vertebrates, with orthologs identified in mammals, birds, and reptiles, reflecting an ancient evolutionary origin tied to the emergence of the three-domain structure in the albumin family. Sequence alignments reveal high conservation in core binding domains, enabling functional assays to demonstrate retained ligand-binding capacity for fatty acids and hormones despite species divergences. In reptiles, albumin evolution shows variability in domain number and gene duplication, such as absences in squamates alongside retained serum albumin in other lineages like turtles and crocodilians. Human serum albumin (HSA) and bovine serum albumin (BSA) exhibit 76% sequence identity, with differences including variations in α-helix count, hydrophilicity, and ligand-binding affinities that influence bulk solution behavior and interfacial properties. While both display N-linked glycosylation—HSA at non-canonical sites Asn68 and Asn123 bearing complex glycans—the extent and impact differ, affecting stability and interactions in physiological contexts. Binding pocket variations lead to distinct affinities for compounds like benzoates and coumarin derivatives, with BSA often showing higher hydrophobicity-driven aggregation. Serum albumin concentrations typically range from 450 to 700 µM across vertebrate species, with half-life exhibiting allometric scaling proportional to body mass, extending from days in rodents to weeks in larger mammals. In veterinary medicine, hypoalbuminemia serves as a marker of severe hepatic dysfunction in canines, occurring when liver synthetic capacity drops below 25% of normal, often complicating chronic liver diseases like copper-associated hepatopathy. Recombinant production of non-human serum albumins, such as canine or equine variants, utilizes yeast like Pichia pastoris or plant systems like Nicotiana benthamiana to yield animal-free proteins with native-like structure for veterinary applications, bypassing risks of pathogen transmission from plasma-derived sources. These methods enable scalable yields while preserving species-specific binding traits, supporting uses in cell culture and therapeutics tailored to non-human species.

Non-Serum Albumins

Ovalbumin constitutes the predominant protein in chicken egg white, accounting for roughly 54% of its total protein content, with a molecular mass of 45 kDa and a single N-linked glycosylation site that contributes to its solubility and stability. Primarily functioning as a nutrient reservoir, it supplies amino acids and potentially protective factors during embryonic development, though it lacks protease inhibitory activity despite structural homology to the serpin superfamily. Alpha-lactalbumin, present in mammalian milk as a whey protein fraction, has a molecular mass of about 14 kDa and exhibits structural homology to , featuring a two-domain architecture with calcium-binding capability. It acts as a regulatory subunit of galactosyltransferase, modifying the enzyme's specificity to synthesize lactose, thereby facilitating milk carbohydrate production essential for neonatal nutrition. In plants, albumins such as 2S seed storage proteins serve as nutrient reserves, typically comprising small (10-20 kDa), disulfide-bond-rich heterodimers abundant in sulfur-containing amino acids, which are degraded during seed germination to support early growth. These differ structurally from animal albumins, lacking the multi-domain heart-shaped fold of serum albumins, and instead adopt compact beta-sheet-rich conformations for stability in desiccated seeds; leaf-specific albumins, though less common, may fulfill transient storage roles in vegetative tissues. While broadly classified as albumins due to water solubility, these non-serum forms reflect functional divergence, with phylogenetic studies indicating the core albumin domain architecture in vertebrates originated from ancient gene duplications predating mammalian radiation, adapting to tissue-specific demands over evolutionary timescales.

Clinical and Pathophysiological Aspects

Hypoalbuminemia and Associated Conditions

Hypoalbuminemia, defined as a serum albumin concentration below 3.5 g/dL, primarily results from reduced hepatic synthesis, excessive renal or enteric losses, or accelerated catabolism in inflammatory and catabolic states. In liver diseases such as cirrhosis, hepatocyte dysfunction impairs albumin production, which normally occurs at a rate of 10-15 g per day in healthy adults. This synthetic deficit is compounded in chronic liver failure, where cohort studies link hypoalbuminemia to progressive fibrosis and portal hypertension, independent of nutritional status. Renal hypoalbuminemia predominates in nephrotic syndrome, characterized by glomerular barrier defects causing urinary albumin excretion exceeding 3.5 g per day, overwhelming resynthetic capacity. Enteric losses via protein-losing enteropathy or severe burns further deplete intravascular pools through exudative mechanisms. As a negative acute phase reactant, albumin synthesis is transcriptionally downregulated during systemic inflammation via cytokines like interleukin-6, with levels inversely correlating to C-reactive protein elevations in cohort analyses of septic patients. These pathophysiological processes culminate in interstitial fluid shifts due to diminished colloid oncotic pressure, manifesting as peripheral edema, ascites, and pleural effusions in conditions like cirrhosis or heart failure. Reduced albumin also impairs ligand binding for fatty acids, bilirubin, and pharmaceuticals, potentially exacerbating toxicity in hypoalbuminemic states. Longitudinal ICU cohort studies, involving thousands of critically ill patients, associate admission hypoalbuminemia with 2- to 4-fold increased mortality odds, attributable to intertwined inflammation, malnutrition, and multiorgan failure rather than isolated oncotic effects. Dehydration can artifactually elevate measured albumin concentrations, masking underlying hypoalbuminemia; evaluation of the albumin-to-total protein ratio or globulin fractions helps unmask such discrepancies in volume-contracted states.

Hyperalbuminemia and Rare Elevations

Hyperalbuminemia, defined as serum albumin concentrations exceeding 5 g/dL, is an uncommon finding, in contrast to the frequent occurrence of hypoalbuminemia in clinical settings. Unlike hypoalbuminemia, which often signals underlying pathology such as liver dysfunction or malnutrition, hyperalbuminemia lacks established disease associations and typically reflects non-pathological or artifactual processes. The primary cause is hemoconcentration due to dehydration, which reduces plasma volume and concentrates albumin without altering its absolute production, as hepatic synthesis remains tightly regulated under normal conditions. Significant fluid loss, such as from excessive sweating, vomiting, or diuretic use, can elevate levels modestly, but values substantially above 5 g/dL are rare even in severe cases. Laboratory errors, including improper sample handling like prolonged venous stasis leading to local concentration gradients, contribute to spurious elevations. True physiological hyperalbuminemia, independent of volume contraction, is exceptionally rare and not linked to overproduction, given albumin's homeostatic control via transcriptional regulation and catabolic feedback. Isolated case reports and cohort analyses describe transient elevations in settings like high-protein diets or polycythemia with hypodipsia, but these resolve with rehydration and lack prognostic implications. Empirical associations with hyperviscosity syndromes are anecdotal and unconfirmed in large studies, distinguishing hyperalbuminemia from gammopathies where paraproteins may interfere with dye-binding assays (e.g., bromcresol green or purple) used in automated analyzers, yielding pseudoelevations. Diagnostic pitfalls arise from automated analyzers' reliance on colorimetric methods, which can overestimate in hemolyzed or lipemic samples, or underestimate in bilirubin excess, though overestimation predominates in reported artifacts. Repeat testing with manual methods or alternative assays, alongside assessment of hydration status via hematocrit or urine specific gravity, is recommended to confirm true elevations, as most resolve without intervention. In retrospective cohorts, hyperalbuminemic patients (≥5 g/dL) showed no increased morbidity beyond dehydration-related risks, underscoring its benign nature.

Diagnostic and Prognostic Implications

Serum albumin concentrations function as a prognostic biomarker in intensive care unit (ICU) settings, where levels below 2.5 g/dL correlate with elevated short-term mortality risks, including ICU and 28-day outcomes. Serial measurements in critically ill patients reveal that hypoalbuminemia, particularly under 2.0 g/dL, independently predicts higher mortality rates compared to normoalbuminemic cohorts, with optimal cutoffs around 2.95 g/dL for 28-day prognosis based on receiver operating characteristic analyses. These associations, drawn from cohort studies and meta-analyses, underscore relative risks approximating threefold for low-albumin groups, though primarily correlative—reflecting multifactorial contributors like capillary leakage, dilution, and synthetic deficits rather than establishing albumin as a direct causal mediator of outcomes. In liver disease risk stratification, albumin integrates into the (MELD) score, where reductions signal synthetic hepatic impairment and amplify overall prognostic scores for short-term survival; modified MELD-albumin variants further refine all-cause mortality predictions beyond baseline MELD. As a negative acute-phase protein, albumin synthesis downregulates during systemic inflammation via cytokine-mediated suppression of hepatocyte production, constraining its diagnostic specificity for acute inflammatory processes amid overlapping etiologies such as malnutrition or renal dysfunction. This reactivity pattern diminishes standalone utility in acute settings but supports serial assessments for monitoring chronic disease trajectories, including frailty indices where persistent hypoalbuminemia signals cumulative physiological decline. Evidence from longitudinal cohorts emphasizes trends over single snapshots, as acute perturbations confound isolated readings without establishing causality. Routine serum albumin assays offer cost-effective biomarker screening due to their accessibility as standard laboratory parameters, facilitating broad risk assessment in resource-limited contexts; however, multifactorial determinants—hepatic, renal, nutritional, and inflammatory—yield low specificity, mandating integration with clinical context and composite scores to mitigate false positives in prognostic modeling.

Therapeutic Uses and Controversies

Established Indications for Administration

Human serum albumin is indicated for volume expansion and complication prevention in select conditions supported by randomized controlled trials demonstrating superiority over crystalloids or standard care, particularly in hypoalbuminemic states with circulatory instability. Primary uses include adjunctive therapy in cirrhosis-related complications, where albumin infusion mitigates renal dysfunction and hemodynamic shifts by enhancing oncotic pressure and vascular integrity. In spontaneous bacterial peritonitis (SBP) among patients with cirrhosis, albumin administration at 1.5 g/kg body weight on diagnosis day followed by 1 g/kg on day 3, alongside antibiotics, reduces the risk of renal impairment from 33% to 10% and mortality from 29% to 10% compared to antibiotics alone, as shown in a multicenter RCT of 126 patients. This benefit stems from albumin's role in preventing bacterial translocation-induced vasodilation and hypovolemia, with meta-analyses confirming consistent reductions in hepatorenal syndrome incidence. For hepatorenal syndrome type 1 in cirrhosis, albumin at 1 g/kg on day 1 followed by 20-40 g daily, combined with vasoconstrictors like terlipressin, improves renal perfusion and short-term survival rates to 40-50% versus 20% with vasoconstrictors alone, per RCTs evaluating vasoconstriction-albumin protocols. Guidelines endorse this for acute kidney injury reversal in decompensated liver disease, where crystalloids fail due to splanchnic sequestration. Therapeutic large-volume paracentesis (>5 L) for refractory requires albumin infusion at 6-8 g per liter of ascites removed to prevent post-paracentesis circulatory dysfunction, with RCTs showing 80-90% reduction in and risks compared to no replacement. This is attributed to albumin's maintenance of intravascular volume during rapid ascitic fluid shifts. As an adjunct to , 4-5% or 20-25% albumin solutions replace removed plasma volume at 1-1.5 times the exchange volume, preventing in procedures for conditions like , where RCTs and guidelines support its use over crystalloids for sustained hemodynamic stability. In burn resuscitation, albumin is incorporated after initial crystalloid phases (e.g., modified ) once capillary leak stabilizes (typically 8-12 hours post-injury), with meta-analyses of controlled trials indicating reduced fluid requirements and improved net versus crystalloids alone in severe burns (>30% TBSA). Dosing is 0.5-1 g/kg in 5% solutions for acute volume support. Typical acute dosing across indications is 1 g/kg of 20-25% solution for rapid expansion, while chronic maintenance uses 4-5% iso-oncotic formulations at 20-40 g daily, titrated to hemodynamic response and serum levels >2.5 g/dL.

Comparative Efficacy with Crystalloids

Albumin maintains intravascular due to its molecular size and negative charge, resulting in a plasma of 16 to 20 hours, compared to 20 to 40 minutes for crystalloids in euvolemic states, which rapidly distribute across compartments and necessitate higher volumes for equivalent expansion. This oncotic persistence theoretically minimizes interstitial and supports hemodynamic stability in hypovolemic states by reducing fluid shifts, as crystalloids alone often lead to 2- to 3-fold greater extravascular accumulation. In surgical and hypovolemic subgroups, albumin has demonstrated faster resolution of and reduced vasopressor requirements versus crystalloids, attributed to sustained . Despite these pharmacokinetic advantages, meta-analyses of randomized controlled trials reveal no overall mortality benefit from albumin over crystalloids in critically ill patients requiring fluid . The 2018 Cochrane review of 105 trials involving over 15,000 participants found colloids like albumin yielded little or no difference in all-cause mortality (risk ratio 0.99, 95% CI 0.94-1.04) or organ failure incidence compared to crystalloids. Similarly, sepsis-focused syntheses confirm equivalent survival rates, with albumin failing to reduce 28- or 90-day mortality despite potential short-term hemodynamic gains. Albumin infusions cost 10- to 27-fold more than equivalent crystalloid volumes, with adjusted expenses around 0.6 USD per 100 mL for saline versus substantially higher for albumin, limiting feasibility in resource-constrained environments. Potential adverse effects include dilutional , as albumin administration prolongs activated (APTT) and may impair clot formation by displacing factors or reducing platelet function, particularly in large-volume . These risks, combined with absent advantages, underscore cautious use favoring crystalloids as first-line unless specific oncotic deficits justify albumin.

Key Clinical Trials and Debates

The Saline versus Albumin Fluid Evaluation (SAFE) trial, a 2004 multicenter involving 6,997 critically ill patients in and , compared 4% albumin with 0.9% saline for fluid. It reported no significant difference in 28-day all-cause mortality between groups (726 deaths in the albumin arm versus 729 in saline; relative risk [RR] 0.99, 95% [CI] 0.91-1.09). A pre-specified subgroup analysis in patients with severe suggested a potential mortality benefit with albumin (RR 0.71, 95% CI 0.52-0.97), but this was exploratory, underpowered due to only 1,218 participants in that subgroup, and not replicated in subsequent larger trials, raising skepticism about its reliability amid risks of type I error in post-hoc analyses. The Albumin Italian Outcome Sepsis (ALBIOS) trial, published in 2014, randomized 1,818 patients with severe or across 100 Italian ICUs to receive either crystalloids alone or crystalloids plus 20% albumin targeting levels above 30 g/L after initial resuscitation. No significant difference emerged in 28-day mortality (31.8% in albumin group versus 32.0% in crystalloid group; [HR] 0.99, 95% CI 0.85-1.15) or 90-day mortality (HR 1.01, 95% CI 0.88-1.16), despite protocolized albumin use improving in some measures. The trial's early termination for futility after has drawn critique for potentially underpowering detection of smaller effects, though the point estimates closely aligned with null findings from SAFE, supporting the empirical absence of broad survival benefit in . In cirrhosis-related decompensation, the ANSWER trial (2018, with follow-up analyses extending to 2021) evaluated long-term albumin supplementation (1 g/kg twice monthly) versus standard care in 440 outpatients with decompensated and . It demonstrated a significant reduction in hospitalizations for or refractory (HR 0.48, 95% CI 0.32-0.71) and a trend toward lower mortality (HR 0.61, 95% CI 0.40-0.91 over 18 months), attributed to paracentesis-sparing effects and stabilization of rather than direct correction. This contrasts with contexts, where often reflects capillary leak and inflammation as a marker of severity rather than a causal target; randomized evidence indicates that aggressively normalizing albumin levels fails to improve , underscoring the fallacy of treating the surrogate without addressing underlying pathophysiology.30099-5/fulltext)00173-8/fulltext) Debates persist regarding publication and sponsorship biases in albumin trials, with industry funding (prevalent in over 70% of colloid studies) linked to selective reporting of favorable subgroups and underemphasis of null primary endpoints, potentially inflating perceived benefits for this costly intervention. Meta-analyses reinforce the null hypothesis for routine albumin in broad sepsis resuscitation, showing no mortality reduction versus crystalloids (pooled RR 0.98-1.01 across large RCTs), while niche applications like cirrhosis paracentesis remain evidence-based exceptions amid calls for independent trials to mitigate funding influences.01584-9/fulltext)

Applications Beyond Medicine

Forensic Detection Methods

In , the precipitin test, pioneered by Paul Uhlenhuth in 1901, relies on species-specific antibodies generated against serum proteins such as albumin to differentiate from animal bloodstains through visible precipitin lines formed in gel diffusion assays. This immunological method targets conserved yet species-distinct epitopes on albumin, enabling identification of biological evidence origin in criminal investigations. Subsequent advancements include enzyme-linked immunosorbent assays (ELISA) using monoclonal anti-albumin antibodies, which provide higher sensitivity and specificity for detecting albumin in degraded or environmentally exposed samples, such as buried bloodstains up to several years old. These assays facilitate species differentiation by quantifying albumin cross-reactivity, with minimal false positives when optimized for forensic substrates like blood or saliva. Albumin's structural stability in such samples—resisting denaturation better than many globular proteins—allows reliable antibody binding, though confirmatory integration with DNA profiling is recommended to address potential cross-species reactivity. In forensics, immunoassays targeting albumin, such as lateral flow devices, detect adulteration or illegal in traditional medicines by identifying the protein in diverse matrices including serum, , , and from confiscated products. These portable tests exploit albumin's abundance and antigenicity for rapid, on-site verification, supporting enforcement against . Proteomic methods, employing on tryptic digests of albumin peptides, extend these capabilities by enabling multiplexed identification and species attribution in trace or mixed evidence, surpassing traditional immunoassays in resolving degraded proteomes. Such approaches profile albumin isoforms alongside other markers, providing empirical sequence data for forensic validation.

Industrial, Research, and Emerging Uses

(BSA) functions as a reference standard for protein quantification in biochemical assays and as a blocking to minimize non-specific binding in immunoassays and surfaces. It also stabilizes proteins in buffers and supports applications in diagnostics and . Recombinant (rHSA), produced via yeast or plant expression systems, supplements serum-free media to deliver nutrients, maintain stability, and enhance proliferation in mammalian cells, serving as a xeno-free substitute for BSA or plasma-derived HSA. evaluations confirm rHSA's growth-promoting effects on lines like NRK fibroblasts and SCC-9 epithelial cells, with plant-derived variants boosting CHO cell antibody yields by up to 92% compared to plasma HSA. Albumin nanoparticles enable through passive tumor accumulation via the , leveraging albumin's and ligand-binding properties. A clinical benchmark is nab-paclitaxel (Abraxane), albumin-bound nanoparticles averaging 130 nm, approved by the FDA on January 7, 2005, for post-chemotherapy failure. Emerging formulations conjugate albumin with metals or folates for selective uptake, demonstrating reduced in preclinical models. In , albumin hydrogels and electrospun scaffolds provide biocompatible matrices that degrade synchronously with tissue regeneration, supporting adhesion and vascularization. Hemin-doped fibers promote neural differentiation, while composite scaffolds with or nanoclusters enhance mechanical stability for and bone repair applications. Industrial-scale purification of relies on Cohn cold of plasma, a multi-step process yielding high-purity fractions since its development in the 1940s. The global albumin market reached USD 6.80 billion in 2024, with -driven production expanding due to biotech demands, projecting growth to USD 11.54 billion by 2032 amid scalable innovations in recombinant variants.

Historical and Nomenclature Context

Discovery and Early Isolation

In 1827, British physician Richard Bright described the presence of heat-coagulable protein—later identified as —in the of patients exhibiting (edema) and renal , establishing a key diagnostic association between and through simple thermal precipitation tests. This observation built on earlier anecdotal reports of urinary protein but provided the first systematic clinical , emphasizing albumin's coagulable nature upon heating. By the 1930s, advancements in analytical techniques enabled the separation of albumin from other serum proteins. Swedish Arne Tiselius developed moving-boundary in his 1930 doctoral thesis, which by the late 1930s allowed fractionation of human serum into distinct components: albumin (comprising approximately 55% of total protein) and various globulins (α, β, γ). This method revealed albumin's electrophoretic mobility and homogeneity relative to heterogeneous globulins, facilitating initial characterizations of its physicochemical properties. Concurrently, (BSA) emerged as a model for experimental studies, isolated via dialysis against water to precipitate globulins, aiding early insights into albumin's stability and solubility across species. Large-scale purification advanced during through Edwin Cohn's cold process, initiated in 1940 under U.S. military commission. This multistep precipitation method, exploiting pH, temperature, and gradients, yielded highly pure (HSA) solutions stable for transfusion, with yields sufficient for clinical volumes (e.g., 20-25 g/L plasma). Cohn's technique, refined by 1943-1944, separated albumin (fraction V) from immunoglobulins and other proteins, enabling its first widespread medical application while confirming chemical similarities between human and bovine variants. Molecular characterization progressed in the mid-20th century, with the complete of HSA elucidated in the 1970s through peptide mapping and , revealing a 585-residue polypeptide encoded by a single on 4q11-q22. Nucleotide sequencing of the , achieved via cDNA by the early 1980s, confirmed its 14-exon structure and evolutionary conservation. The three-dimensional of HSA was resolved in 1994 at 2.5 Å resolution (PDB 1AO6), disclosing a heart-shaped with three homologous α-helical domains and multiple ligand-binding sites, marking a pivotal empirical in .

Etymology and Terminology Evolution

The term albumin originates from the Latin albumen, denoting "," derived from albus ("white"), reflecting its initial association with the coagulable protein fraction in avian egg whites observed to turn opaque upon heating. This etymological link underscores early recognition of albumins as water-soluble proteins distinguishable by their heat-induced , a property noted in egg whites since at least the when chemists began classifying proteins based on and behaviors. In biochemical , "albumin" evolved in the to specify a class of simple, sulfur-containing, water-soluble proteins soluble in pure water but precipitating in concentrated salt solutions, contrasting with globulins—less soluble proteins that form globules upon , a distinction formalized through fractional precipitation techniques like saturation. Swedish chemist , active in protein terminology during this era, contributed to broader classifications, with "albumin" entering usage around 1836 for these soluble fractions in blood and other fluids. By the mid-20th century, precision in led to "" as the standard designation for the major plasma protein (approximately 66 kDa in humans), emphasizing its role in vertebrate blood while distinguishing it from homologs like ovalbumin; this aligns with IUPAC definitions of albumins as plasma transport proteins for ions, fatty acids, and metabolites. The terminology exhibits cross-linguistic consistency in scientific literature, rooted in Latin and adopted uniformly in English, French (albumine), and German (Albumin), facilitating global biochemical discourse without significant variation.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK459198/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395139/
  3. https://www.mdpi.com/1422-0067/22/18/10086
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8685822/
  5. https://www.uniprot.org/uniprotkb/P02768/entry
  6. https://www.mdpi.com/2673-8392/1/1/9
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11090807/
  8. https://academic.oup.com/peds/article/12/6/439/1487202
  9. https://www.nature.com/articles/s41598-018-19610-9
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC10726258/
  11. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/355/466/a9080pis.pdf
  12. https://www.jbc.org/article/S0021-9258%2819%2944056-8/abstract
  13. https://www.jbc.org/article/S0021-9258%2819%2944056-8/pdf
  14. https://pubs.acs.org/doi/10.1021/jp409936v
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC5130592/
  16. https://www.jbc.org/article/S0021-9258%2820%2945983-6/fulltext
  17. https://www.nature.com/articles/s41598-024-76544-1
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC4959682/
  19. https://www.sciencedirect.com/topics/immunology-and-microbiology/oncotic-pressure
  20. https://professionaleducation.blood.ca/en/transfusion/clinical-guide/albumin
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4956071/
  22. https://derangedphysiology.com/main/cicm-primary-exam/cardiovascular-system/Chapter-471/starling-forces-and-fluid-exchange-microcirculation
  23. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1046/j.1365-2044.1998.00488.x
  24. https://derangedphysiology.com/main/cicm-primary-exam/body-fluids-and-electrolytes/Chapter-013/osmotic-pressure-and-oncotic-pressure
  25. https://www.sciencedirect.com/topics/nursing-and-health-professions/oncotic-pressure
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC5480655/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC5491222/
  28. https://febs.onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2005.04883.x
  29. https://www.sciencedirect.com/science/article/pii/S2665928X2300020X
  30. https://www.sciencedirect.com/science/article/abs/pii/S0301462210000608
  31. https://annalsofintensivecare.springeropen.com/articles/10.1186/2110-5820-3-4
  32. https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2008.04.057
  33. https://pubmed.ncbi.nlm.nih.gov/12924939/
  34. https://pubmed.ncbi.nlm.nih.gov/21480235/
  35. https://www.sciencedirect.com/science/article/abs/pii/101113449380179D
  36. https://www.sciencedirect.com/science/article/pii/S0014579308003967
  37. https://pubmed.ncbi.nlm.nih.gov/8458588/
  38. https://www.nature.com/articles/srep22104
  39. https://pubmed.ncbi.nlm.nih.gov/34638659/
  40. https://pubmed.ncbi.nlm.nih.gov/21167901/
  41. https://www.sciencedirect.com/science/article/abs/pii/S1871402115000855
  42. https://pubmed.ncbi.nlm.nih.gov/19330257/
  43. https://www.pnas.org/doi/10.1073/pnas.78.12.7657
  44. https://www.sciencedirect.com/science/article/abs/pii/S1055790322000483
  45. https://www.researchgate.net/publication/354081552_Human_versus_Bovine_Serum_Albumin_A_Subtle_Difference_in_Hydrophobicity_Leads_to_Large_Differences_in_Bulk_and_Interface_Behavior
  46. https://www.semanticscholar.org/paper/Comparison-of-binding-characteristics-of-human-and-Matsushita-Kijima/511236a46a9b2daec586b1f8fe78004f8f045bac
  47. https://www.mdpi.com/2673-4125/5/3/27
  48. http://www.researchtrends.net/tia/article_pdf.asp?in=0&vn=21&tid=40&aid=6577
  49. https://academic.oup.com/peds/article/19/7/291/1557019
  50. https://www.dvm360.com/view/a-stepwise-approach-to-hypoalbuminemia
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC6524396/
  52. https://www.phenotypeca.com/product/albumin/
  53. https://www.nature.com/articles/s44383-025-00005-5
  54. https://aiche.onlinelibrary.wiley.com/doi/10.1002/btpr.1990
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC5241407/
  56. https://www.worthington-biochem.com/products/ovalbumin/manual
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC5934683/
  58. https://www.sciencedirect.com/topics/food-science/lactalbumin
  59. https://www.mdpi.com/1420-3049/25/4/873
  60. https://www.ncbi.nlm.nih.gov/books/NBK526080/
  61. https://www.medmastery.com/guides/liver-lab-clinical-guide/everything-you-need-know-about-albumin-and-liver-function
  62. https://pubmed.ncbi.nlm.nih.gov/30288759/
  63. https://pubmed.ncbi.nlm.nih.gov/16534226/
  64. https://www.ncbi.nlm.nih.gov/books/NBK519570/
  65. https://aspenjournals.onlinelibrary.wiley.com/doi/10.1002/jpen.1451
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC9045521/
  67. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.770674/full
  68. https://www.sciencedirect.com/topics/nursing-and-health-professions/protein-blood-level
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC8199105/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC7150071/
  71. https://www.sciencedirect.com/science/article/abs/pii/S0009898104002050
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC2658796/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC6437285/
  74. https://jlpm.amegroups.org/article/view/7945/html
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC11349147/
  76. https://www.sciencedirect.com/science/article/pii/S001236922400285X
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC2719274/
  78. https://www.nejm.org/doi/full/10.1056/NEJM199908053410603
  79. https://www.aafp.org/pubs/afp/issues/2022/1000/mbtn-albumin-bacterial-peritonitis.html
  80. https://stanfordhealthcare.org/content/dam/SHC/health-care-professionals/medical-staff/medstaff-weekly/20170315-guidelines-for-intravenous-albumin-administration.pdf
  81. https://consultqd.clevelandclinic.org/diagnosis-and-management-of-ascites-spontaneous-bacterial-peritonitis-and-hepatorenal-syndrome
  82. https://www.ejinme.com/article/S0953-6205%2823%2900232-7/fulltext
  83. https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-cc-albumin-decision-tool.pdf
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC4851230/
  85. https://www.medintensiva.org/es-download-pdf-S0210569116000024
  86. https://journals.lww.com/ejanaesthesiology/fulltext/2016/07000/the_half_life_of_infusion_fluids__an_educational.2.aspx
  87. https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-014-0038-4
  88. https://www.ccjm.org/content/91/7/405
  89. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000567.pub7/full
  90. https://jamanetwork.com/journals/jama/fullarticle/1752245
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC9907763/
  92. https://journals.lww.com/md-journal/fulltext/2024/12270/human_albumin_for_adults_with_sepsis__an_updated.31.aspx
  93. https://pubmed.ncbi.nlm.nih.gov/32828672/
  94. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0114666
  95. https://www.sciencedirect.com/science/article/pii/S1441277223012838
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC4782842/
  97. https://criticalcare.queensu.ca/sites/criticalcare/files/inline-files/SAFE_Trial_NEJM_2004.pdf
  98. https://www.nejm.org/doi/full/10.1056/NEJMoa1305727
  99. https://pubmed.ncbi.nlm.nih.gov/24635772/
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC10743695/
  101. https://www.americanforensics.org/uhlenhuth-test/
  102. https://www.sciencedirect.com/science/article/abs/pii/S0379073804002701
  103. https://www.sciencedirect.com/science/article/pii/037907389290006I
  104. https://www.semanticscholar.org/paper/Species-identification-of-blood-and-saliva-stains-Fletcher-Dolton/ab06695fc0852ef7ea6bf46d8cced02093e73ded
  105. https://www.mdpi.com/2076-3417/11/8/3393
  106. https://www.researchgate.net/publication/238743390_Development_of_a_field_test_for_the_detection_of_illegal_bear_products
  107. https://www.nature.com/articles/srep17475
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC3578717/
  109. https://www.sciencedirect.com/science/article/pii/S1872497321000673
  110. https://www.thermofisher.com/us/en/home/life-science/cell-culture/mammalian-cell-culture/media-supplements/bovine-serum-albumin.html
  111. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/bovine-serum-albumin
  112. https://www.merckmillipore.com/SR/en/technical-documents/technical-article/clinical-testing-and-diagnostics-manufacturing/ivd-manufacturing/probumin-bovine-serum-albumin-powders-and-solutions
  113. https://www.grifols.com/en/albumin
  114. https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/cell-culture-media-preparation/human-serum-albumin
  115. https://invitria.com/type/recombinant-human-albumin/
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC3449618/
  117. https://invitria.com/resources/optimizing-antibody-production-in-animal-free-media-with-the-supplementation-of-recombinant-human-albumin-cellastim/
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC11246635/
  119. https://www.drugs.com/history/abraxane.html
  120. https://www.aetna.com/cpb/medical/data/800_899/0834.html
  121. https://www.nature.com/articles/s41598-025-19075-7
  122. https://www.mdpi.com/1422-0067/26/17/8297
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC9502107/
  124. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1137145/full
  125. https://pubs.acs.org/doi/10.1021/acsami.7b18179
  126. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-024-03022-1
  127. https://www.sciencedirect.com/science/article/pii/S1045105625000405
  128. https://www.fortunebusinessinsights.com/albumin-market-102637
  129. https://www.precedenceresearch.com/press-release/albumin-market
  130. https://academic.oup.com/ndt/article/18/7/1281/1809803
  131. https://www.nobelprize.org/prizes/chemistry/1948/tiselius/facts/
  132. https://academic.oup.com/labmed/article/40/10/627/2504812
  133. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/317/056/b2518pis.pdf
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC10331509/
  135. https://pmc.ncbi.nlm.nih.gov/articles/PMC1685723/
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC345663/
  137. https://www.etymonline.com/word/albumin
  138. https://www.merriam-webster.com/dictionary/albumin
  139. https://www.e3s-conferences.org/articles/e3sconf/pdf/2021/85/e3sconf_icmed2021_01086.pdf
  140. https://goldbook.iupac.org/terms/view/AT06761
Add your contribution
Related Hubs
User Avatar
No comments yet.